Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACEVUOTCMKTS:ACKIUOTCMKTS:ADRAUNASDAQ:EBACUOTCMKTS:SCCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACEVUACE Convergence Acquisition$9.77-0.1%$9.77$9.27▼$10.80N/AN/A2,197 shs800 shsACKIUAckrell SPAC Partners I$10.36-0.2%$10.36$8.14▼$11.35N/AN/A4,697 shs400 shsADRAUAdara Acquisition$0.02$0.02$0.02▼$11.20N/AN/A1,795 shsN/AEBACUEuropean Biotech Acquisition$11.30$9.84$9.75▼$10.49N/AN/A2,500 shs5,714 shsSCCBSachem Capital Corp. 7.125% Not$24.980.0%$24.98$24.50▼$25.49N/AN/A3,395 shs400 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACEVUACE Convergence Acquisition0.00%0.00%0.00%0.00%0.00%ACKIUAckrell SPAC Partners I0.00%0.00%0.00%0.00%0.00%ADRAUAdara Acquisition0.00%0.00%0.00%0.00%0.00%EBACUEuropean Biotech Acquisition0.00%0.00%0.00%0.00%0.00%SCCBSachem Capital Corp. 7.125% Not0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACEVUACE Convergence AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AACKIUAckrell SPAC Partners IN/AN/AN/AN/AN/AN/AN/AN/AADRAUAdara AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AEBACUEuropean Biotech AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ASCCBSachem Capital Corp. 7.125% NotN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACEVUACE Convergence Acquisition 0.00N/AN/AN/AACKIUAckrell SPAC Partners I 0.00N/AN/AN/AADRAUAdara Acquisition 0.00N/AN/AN/AEBACUEuropean Biotech Acquisition 0.00N/AN/AN/ASCCBSachem Capital Corp. 7.125% Not 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACEVUACE Convergence AcquisitionN/AN/AN/AN/AN/AN/AACKIUAckrell SPAC Partners IN/AN/AN/AN/AN/AN/AADRAUAdara AcquisitionN/AN/AN/AN/AN/AN/AEBACUEuropean Biotech AcquisitionN/AN/AN/AN/AN/AN/ASCCBSachem Capital Corp. 7.125% NotN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACEVUACE Convergence AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AACKIUAckrell SPAC Partners IN/AN/A0.00∞N/AN/AN/AN/AN/AADRAUAdara AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AEBACUEuropean Biotech AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ASCCBSachem Capital Corp. 7.125% NotN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACEVUACE Convergence AcquisitionN/AN/AN/AN/AN/AACKIUAckrell SPAC Partners IN/AN/AN/AN/AN/AADRAUAdara AcquisitionN/AN/AN/AN/AN/AEBACUEuropean Biotech AcquisitionN/AN/AN/AN/AN/ASCCBSachem Capital Corp. 7.125% NotN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACEVUACE Convergence AcquisitionN/AACKIUAckrell SPAC Partners IN/AADRAUAdara AcquisitionN/AEBACUEuropean Biotech AcquisitionN/ASCCBSachem Capital Corp. 7.125% Not2.08%Insider OwnershipCompanyInsider OwnershipACEVUACE Convergence AcquisitionN/AACKIUAckrell SPAC Partners IN/AADRAUAdara AcquisitionN/AEBACUEuropean Biotech AcquisitionN/ASCCBSachem Capital Corp. 7.125% NotN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACEVUACE Convergence Acquisition3N/AN/ANot OptionableACKIUAckrell SPAC Partners I3N/AN/ANot OptionableADRAUAdara Acquisition847N/AN/ANot OptionableEBACUEuropean Biotech Acquisition2N/AN/ANot OptionableSCCBSachem Capital Corp. 7.125% Not34N/AN/ANot OptionableEBACU, SCCB, ACEVU, ACKIU, and ADRAU HeadlinesRecent News About These CompaniesSachem Capital Corp. 7.125% Notes due 2024 (SCCB)January 28, 2022 | nasdaq.comMedia Sentiment Over TimeEBACU, SCCB, ACEVU, ACKIU, and ADRAU Company DescriptionsACE Convergence Acquisition OTCMKTS:ACEVU$9.77 -0.01 (-0.10%) As of 11/22/2022ACE Convergence Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on businesses in the IT infrastructure software and semiconductor sectors. ACE Convergence Acquisition Corp. was incorporated in 2020 and is based in Wilmington, Delaware.Ackrell SPAC Partners I OTCMKTS:ACKIU$10.36 -0.02 (-0.19%) As of 08/31/2022Ackrell SPAC Partners I Co. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on alcoholic and non-alcoholic beverage and wellness sectors. Ackrell SPAC Partners I Co. was founded in 2018 and is Claymont, Delaware.Adara Acquisition OTCMKTS:ADRAU$0.02 0.00 (0.00%) As of 03/17/2023Adara Acquisition Corp. was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any industry, it currently intends to concentrate its search for a target business operating in the consumer products and related industries.European Biotech Acquisition NASDAQ:EBACUEuropean Biotech Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands.Sachem Capital Corp. 7.125% Not OTCMKTS:SCCB$24.98 -0.01 (-0.04%) As of 06/28/2024since 2010, sachem capital has been financing opportunistic real estate transactions in the new england area. sachem capital provides quick, short-term bridge capital for real estate investors, builders or developers who need immediate funding or to solve an immediate problem. our creative real estate financing solutions are developed exclusively for those seeking alternatives to conventional bank loans. the executive team has extensive experience in real estate acquisitions, investments, management and development. our hands-on managers have the expertise to quickly assess complex opportunities and non-conventional situations to deliver a closing product that is efficient and opportunistic to our borrowers, and profitable to our shareholders. sachem capital was listed on the nyse on february 10, 2017. the company was designed to address the constant volatility and instability in today's financial markets. we are exited to share with you this extraordinary opportunity to seize favorabl More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
